Kenneth Obiaja
Family Medicine · New Port Richey, FLNPI 1639342363
Payments from drug & device makers
Across 151 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$407
- Exact Sciences$397
- Boston Scientific$379
- AstraZeneca$341
- Pfizer$289
- Amgen$272
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,01791%
- Education$1003%
- Gifts$1695%
- Other$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $407 |
| Exact Sciences | 22 | $397 |
| Boston Scientific | 3 | $379 |
| AstraZeneca | 17 | $341 |
| Pfizer | 17 | $289 |
| Amgen | 16 | $272 |
| Lilly USA, LLC | 13 | $241 |
| GSK | 13 | $222 |
| Tosoh Bioscience, Inc. | 1 | $169 |
| AbbVie(2 entities) | 9 | $153 |
| Astellas Pharma US Inc | 2 | $119 |
| Abbott | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Si-bone, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $20 |
| Novartis | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Welch Allyn | 1 | $14 |
| Merck | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- S-ICD System Magnet$174
- Rhythmia Mapping System$174
- TSH, ST AIA-PACK$169
- TSH3G, AIA-PACK Calibrator Set$169
- FOL, AIA-PACK$169
- FOL, AIA-PACK, Sample Diluting Solution$169
- T4, AIA-PACK Calibrator Set$169
How this compares
$3,300 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $154,068 |
| OzempicSemaglutide | 112 | $131,896 |
| MounjaroTirzepatide | 65 | $86,094 |
| JardianceEmpagliflozin | 39 | $50,625 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $36,777 |
| Repatha SureclickEvolocumab | 36 | $28,254 |
| JanuviaSitagliptin Phosphate | 18 | $26,708 |
| XareltoRivaroxaban | 23 | $26,491 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $22,488 |
| MyrbetriqMirabegron | 24 | $20,641 |
| TrulicityDulaglutide | 12 | $11,327 |
| Levothyroxine Sodium | 623 | $7,316 |
| Atorvastatin Calcium | 722 | $7,299 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,074 |
| VascepaIcosapent Ethyl | 11 | $6,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $289 | $154,068115 claims |
| Novo NordiskOzempic | $407 | $131,896112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $241 | $97,42177 claims |
| Boehringer IngelheimJardiance | $20 | $50,62539 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $222 | $43,85145 claims |
| MerckJanuvia | $14 | $26,70818 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $20,64124 claims |
| AbbVieSynthroid | $153 | $6,30987 claims |
| AstraZenecaSymbicort | $341 | $2,48011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in New Port Richey
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.